BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Clinical trials for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New implant tested to shrink tough pancreatic tumors before surgery
Disease control Recruiting nowThis early-stage study is testing a new implant called PTM-101, which is placed near the pancreas to deliver chemotherapy directly to the tumor. The goal is to see if this approach, combined with standard pre-surgery chemo, is safe and can shrink tumors in people with borderline …
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: PanTher Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for tough pancreatic cancers: trial tests Immune-Boosting drug combo
Disease control Recruiting nowThis study is testing whether adding two new drugs (zimberelimab and quemliclustat) to standard chemotherapy can help people with pancreatic cancer that is difficult or impossible to remove with surgery. The new drugs aim to boost the immune system's ability to fight the cancer. …
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Triple attack on pancreatic cancer before surgery aims to extend lives
Disease control Recruiting nowThis study is testing a new three-part treatment for patients with pancreatic cancer that can be surgically removed. Before surgery, patients receive a combination of chemotherapy, immunotherapy, and targeted radiation. The goal is to see if this intensive approach helps control …
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New drug sequence aims to make inoperable pancreatic tumors removable
Disease control Recruiting nowThis study is testing whether giving two different chemotherapy combinations in sequence can better shrink pancreatic tumors that are difficult or impossible to remove with surgery. The goal is to see if this approach makes more tumors operable and improves survival. The trial wi…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
Targeted attack on tough pancreatic cancer shows promise
Disease control Recruiting nowThis study is testing a new three-drug combination for people with a hard-to-treat form of pancreatic cancer that has a specific genetic marker called KRAS G12D. The goal is to shrink tumors before surgery to make them easier to remove completely. The trial will enroll 40 partici…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC